Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4B5 Vaccine in High-Risk Melanoma
NCT00004184Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 1998
- Primary completion
- Jun 2001
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of monoclonal antibody 4B5 anti-idiotype vaccine in melanoma (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Adverse Events and Serious Adverse Events. Started Aug 1998; status: completed.
02
Drugs
monoclonal antibody 4B5 anti-idiotype vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00004184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004184.